FIGURE 3.
Inhibition of Pak1, but not Pak6, inhibits extracellular matrix-specific directional migration of prostate cancer cells. a–f, stable human prostate cancer (PC3) cells expressing shRNA for scrambled (control), Pak1 or Pak6, and control PC3 cells (pBabe-Puro), as well as cells transiently transfected with constitutively active Pak1 (CA-Pak1, Pak1 E493) were subjected to a migration assay utilizing a monolayer scratch recovery assay. Cells were plated on 12-well pates precoated with ECM proteins (0.5 μg/well) such as fibronectin, vitronectin, laminin, secreted protein acidic and rich in cysteine/osteonectin, and bone sialoprotein/osteopontin, respectively, and treated with 50 μm EGF (R&D Systems, Minneapolis, MN). The data are presented as mean ± S.D. n = 3 of quadruplicate experiments. *, p < 0.001; #, p < 0.05; Δ, p < 0.01 versus control experiments within the same group.